Influence of a Silicone Gel (Dermatix®) on Thoracic Scar Formation After Harvesting of Autologous Rib Cartilage

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2007 by University of Schleswig-Holstein.
Recruitment status was  Recruiting
Information provided by:
University of Schleswig-Holstein Identifier:
First received: November 29, 2007
Last updated: NA
Last verified: November 2007
History: No changes posted

So far the evaluation of scar treatment was based on subjective criteria. The patient groups were divided into treated versus non-treated.

In this study we use patients undergoing ear reconstruction with autologous rib cartilage. The thoracic scar of harvesting the rib cartilage is routinely reopened after 3 month during second stage of reconstruction. Therefore we have a ideal model of clinical, physiological and histological scar evaluation in a homologous patient group.

All patients randomly treat one half of the scar with a silicone gel (Dermatix). The other half is untreated as an internal control.

Condition Intervention
Cicatrix, Hypertrophic
Drug: Silicone gel (Dermatix®)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Influence of a Silicone Gel (Dermatix®) on Thoracic Scar Formation After Harvesting of Autologous Rib Cartilage for Standardised Total Ear Reconstruction

Resource links provided by NLM:

Further study details as provided by University of Schleswig-Holstein:

Primary Outcome Measures:
  • Beausang's scar scale, skin elasticity (Cutometer®), skin moisture (Corneometer®), skin color (Chromameter®, Mexameter®), histological evaluation (HE, elastica, actin etc.) [ Time Frame: 45 minutes ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • allergic reaction compliance [ Time Frame: retrospective ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: January 2007
Estimated Study Completion Date: January 2009
Arms Assigned Interventions
Active Comparator: 1
Each patient uses the silicone gel on one half of the scar, leaving the other one blank as an internal control.
Drug: Silicone gel (Dermatix®)
The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
Other Name: Dermatix®


Ages Eligible for Study:   9 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with high grade microtia requiring a reconstruction with autologous rib cartilage

Exclusion Criteria:

  • diabetes mellitus
  • vascular disease
  • known allergic reaction to silicone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00565552

Contact: Stefan Nitsch, MD +49 451 500 ext 2244
Contact: Henning Frenzel, MD +49 451 500 ext 2244

University Hospital Schleswig-Holstein Recruiting
Luebeck, Germany, 23564
Sponsors and Collaborators
University of Schleswig-Holstein
Principal Investigator: Stefan Nitsch, MD University of Schleswig-Holstein
  More Information

Responsible Party: Dr. Stefan Nitsch, University of Schleswig-Holstein Identifier: NCT00565552     History of Changes
Other Study ID Numbers: Dermatix01 
Study First Received: November 29, 2007
Last Updated: November 29, 2007
Health Authority: Germany: Ethics Commission

Keywords provided by University of Schleswig-Holstein:
silicone gel
wound healing

Additional relevant MeSH terms:
Cicatrix, Hypertrophic
Pathologic Processes processed this record on May 30, 2016